Video Q&A: What is autism? - A personal view by Raff, Martin
Martin Raff trained in Medicine at McGill University and 
was a Resident in Neurology at Massachusetts General 
Hospital  when  in  1969  he  became  fascinated  by  the 
nascent  field  of  cellular  immunology  and  abandoned 
medicine to join the laboratory of Avrion Mitchison at 
Mill Hill, London and subsequently at University College 
London,  where  he  made  seminal  contributions  in  the 
biology  of  T  and  B  lymphocytes.  Later,  he  turned  to 
develop  mental neurobiology, which occupied him until 
his retirement from active research in 2003.
It was only after his retirement that he became inter­
ested in the biological basis of autism, when it affected 
his own family. In this interview, he talks, as a biologically 
knowledgeable grandparent, about how he sees the disorder 
and where he thinks research on the condition is leading.
Edited transcript
Your research has been in immunology and neural 
development. What got you interested in autism?
I have a grandson who’s autistic, and that’s the immediate 
reason. But I did train in neurology many years ago and 
what’s interesting is that in those three years I never saw 
a  patient  with  autism,  which  was  very  rare  then.  And 
then I was a developmental neurobiologist for 25 years 
and I never heard a talk on autism, even though it was 
thought to be a brain development problem: there wasn’t 
a single talk in 25 years, which is quite remarkable. Now 
autism  has  increased  greatly  in  prevalence  and  is 
frequently in the news. But it was my grandson, who is 
now 8, who got me interested in the subject.
What are the defining features of autism?
The three core features are a problem with social inter­
actions, which is often the heart of the matter; a problem 
with language; and a tendency to have restricted interests  © 2010 BioMed Central Ltd
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and repeated, stereotypic motor behaviors. That is the so­
called  autistic  triad,  and  you  need  to  have  two  of  the 
three and to develop them by the age of 3 to be con­
sidered autistic.
Is autism just one thing? – Isn’t it a spectrum?
It is a spectrum, and probably the reason, or at least one 
important reason, for the apparent increase in autism is 
that the diagnostic criteria have expanded enormously. At 
the bad end of the spectrum are the classic autistic kids, 
and at the best end of the spectrum are Asperger kids, who 
have much less trouble with language and are often very 
smart. But there is also everything in between. I’m sure 
you have many colleagues with some features of autism.
You have an unorthodox view of how autism 
develops – What is it?
I’m not so sure it’s unorthodox. It starts from the need to 
explain  the  basis  of  the  autistic  triad:  why  do  these 
features  occur  together  in  this  way?  Besides  the  three 
core  features,  there  are  also  often  other  associated 
features ­ seizures in 30%, intellectual impairment in 50% 
and  behavioral  abnormalities  such  as  temper  tantrums 
and feeding and sleeping disorders, and so on, which are 
often found in addition to the core triad.
So I think a major question is what binds the core triad 
together? There is no part of the brain that I’m aware of 
where  an  abnormality  would  explain  this  triad  while 
leaving so much else intact.
A  simple  possibility  would  be  that  there  is  a  funda­
mental problem in the interaction between the child and 
its  parent,  usually  the  mother.  It  has  been  known  for 
many years that if this interaction is seriously disturbed ­ 
if you can’t achieve what’s called joint attention with your 
mother or care giver ­ then you don’t learn to speak, you 
don’t  learn  social  skills,  and  you  develop  restricted 
interests  and,  not  infrequently,  repeated  stereotypic 
movements.
Is there any evidence for this view?
Yes. If a monkey is separated from its mother and other 
monkeys at birth, it becomes autistic: it doesn’t develop 
normal vocalizations or social skills and shows restricted 
interests and repetitive motor activities such as rocking. 
If a child is born deaf, for example, and it is a year or two 
or  three  before  that’s  picked  up,  the  child  has  an 
increased likelihood of developing autistic features; or if a 
child is born blind and this is missed, that too is often 
associated with autistic features. And children who are 
brought up in orphanages, particularly the big orphan­
ages where you don’t get one­on­one care at all, as occurs 
in some Romanian orphanages, for example, these kids 
often  develop  what’s  called  institutional  autism.  So  I 
think  it’s  pretty  clear  that  if  you  interfere  with  the 
child­parent interaction (and other social interactions), 
this can lead to the autistic triad.
Are you saying it’s all the parents’ fault?
Kanner, when he first described autistic behavior in 1943, 
noted in his report that the parents of these children were 
cold and didn’t seem to have an interest in people; you 
can see that he was thinking of blaming the parents. Then 
Bettelheim picked up on the idea and argued that it really 
is the parents’ fault and talked about refrigerator mothers. 
So during the 1950s and 1960s, it was commonly felt that 
autism was an emotional disorder and parents were to 
blame.
Do you think they were wrong?
I think they were right in pointing to the child­parent 
relationship as a problem, but they were pointing to the 
wrong  part  of  the  relationship.  It  is  the  child  that  is 
abnormal, largely for genetic reasons. Autism is the most 
genetic  of  the  neuropsychiatric  disorders.  So  the  child 
seems genetically impaired in his or her ability to inter­
act, and the question is what is the nature of the impair­
ment.  There  are  lots  of  ideas  about  this.  One  is  that 
autistic  children  don’t  process  faces  normally,  which 
inter  feres with their interactions with people. Another is 
that they don’t have the special interest in biological as 
opposed to inanimate things that normal children have. 
And another idea is that they can’t figure out what’s going 
on in somebody else’s mind ­ called mind blindness or a 
‘theory of mind problem’.
I  think  it  is  very  unlikely  that  any  of  those  are  the 
primary problem. I think a more likely explanation is that 
there is a problem with attention ­ a particular type of 
attention problem. There’s increasing evidence that these 
children have what’s called sticky attention, which is a 
problem  with  attention  disengagement.  When  autistic 
children  are  focused  on  something,  it’s  very  hard  to 
disconnect  them  and  get  them  to  focus  on  something 
else.  So  shifting  attention  from  one  thing  to  another 
seems to be a problem.
Is there evidence for ‘sticky attention’?
I think the best evidence for that comes from Landry and 
Bryson. They published a paper in 2004 on a study of 
5­year­old toddlers ­ 30 autistic, 30 Down syndrome, and 
30  neurotypical,  matched  for  IQ,  who  were  taught  to 
focus  on  an  image  on  a  central  computer  screen.  The 
images were just abstract shapes falling through space. 
Then a different abstract image was put up on one of two 
lateral  screens,  and  the  child’s  eye  movements  were 
tracked electronically to see how they quickly looked at 
the  new  image.  If  the  image  on  the  focus  screen  was 
removed at the same time as the new image was put up, 
the  autistic  kids  performed  as  well  as  the  other  two 
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groups, but if the focus image was left on when the new 
image  appeared  on  a  lateral  screen,  then  20%  of  the 
autistic children didn’t look at the new image at all, and, 
of those that did, many were slow to do so, compared 
with the other two groups. In these experiments, there 
were  no  people,  no  faces  and  no  social  interactions, 
suggesting a fundamental problem with attention, and, 
specifically, a problem shifting attention from one thing 
to another.
My grandson had this problem in spades. He developed 
quite  normally  for  a  year  and  a  half  and  then,  starting 
halfway through his second year, over a period of weeks, 
he  dramatically  regressed:  he  stopped  looking  at  you, 
stopped talking, and you could no longer get his attention. 
He could be looking at a wheel spinning or a train going 
round a track or water falling, and you could poke him in 
the arm, flash a light in his eyes, yell in his ears ­ but you 
just couldn’t get his attention. It’s not that he wasn’t paying 
attention ­ he just wasn’t paying attention to you.
There is a lot of interest in the genetic analysis of 
autism - What do you think genetics has to offer?
Well, as I said, it’s the most genetic of the neuropsychiatric 
conditions, and so genetic studies are likely to be the best 
route  to  understanding  the  underlying  neurobiology. 
There  are  already  about  15  genes  that  have  been 
implicated  in  autism.  At  the  extremes,  there  are  two 
classes of genetic influences in multifactorial diseases like 
autism.  There  are  polymorphisms,  which  are  common 
genetic variants that increase your risk a bit, usually less 
than 1.5­fold. These are generally identified by genome­
wide  association  studies  using  SNPs  (single­nucleotide 
polymorphisms) and, for the most part, have not been 
very informative in autism.
The other class consists of rare mutations that greatly 
increase  your  risk  and  are  much  more  informative. 
Thomas Bourgeron, for example, was the first to identify 
neuroligin mutations in some individuals with autism. He 
guessed that there might be abnormalities in synapses in 
autism, and so he looked at two genes, neuroligin 3 and 
neuroligin  4,  which  encode  proteins  that  work  only  at 
synapses, sequencing the protein­coding regions of these 
genes in more than 100 autistic individuals in multiplex 
families (that is, with 2 or more autistic members), as well 
as in a comparable number of neurotypical individuals. 
He found two Swedish families ­ one with a neuroligin 3 
mutation and the other with a neuroligin 4 mutation: in 
each  case,  one  brother  was  autistic  and  the  other  was 
diagnosed  with  Asperger  syndrome.  That  was  the  first 
direct evidence that a mutation that affects a protein that 
works only at synapses can lead to an autism spectrum 
disorder and that the same mutation in the same family 
can lead to both ends of the spectrum. This was a giant 
step  forward.  Subsequently,  mutations  in  genes  that 
encode  proteins  that  interact  with  neuroligins  at 
synapses,  including  neurexin  and  shank  proteins,  have 
been  found  to  predispose  to  autism  and  other  neuro­
psychiatric disorders. I suspect that synaptic defects may 
be at the heart of the problem in many of these disorders 
and  that  defects  in  many  different  genes  can  probably 
contribute to different disorders.
There  are  some  single­gene  disorders,  like  Rett’s 
syndrome, fragile X, and tuberous schlerosis, in which 
autism is part of a more complex neurological syndrome. 
These  are  therefore  called  syndromic  forms  of  autism. 
There are very good mouse models of these, which are 
proving  to  be  very  informative.  It  seems  to  me  that  a 
promising way forward in autism, and in neuropsychiatric 
disorders generally, is to start with a big­effect mutation 
in individuals with the disorder and then try to model the 
disease in an experimental animal such as a mouse. Then 
you can make use of the powerful tools available in mice 
to try to find out what is responsible for the abnormal 
phenotype:  which  part  of  the  brain,  which  types  of 
neurons, which synapses, and which circuits.
Could the very widely publicized connection 
between vaccination and autism account for the 
increase in incidence?
This  of  course  has  been  an  enormous  public  concern, 
particularly for parents or grandparents who have autism 
in the family. Interestingly, in the UK the concern is with 
MMR (mumps, measles, rubella) vaccination, whereas in 
the  US  the  concern  is  with  the  mercury  compound 
(thermasol) in the vehicle.
I  should  have  said  earlier  that  dramatic  regression 
occurs  in  about  30%  of  autistic  kids  (although  minor 
regression occurs much more commonly): they develop 
apparently normally for a year and then in their second 
year  they  lose  what  they  had  and  become  classically 
autistic. After that, they may slowly recover to a variable 
extent,  and  some  may  recover  completely.  So  you  can 
imagine that, if you have a child that’s fine but then, two 
or three weeks after a vaccination, he or she stops looking 
at you and stops talking, it will be difficult to convince 
you that this has nothing to do with the vaccination.
But  there  have  been  ten  or  more  studies  that  show 
pretty unequivocally that vaccination is not involved in 
the autism spectrum disorders. One of the best was from 
Denmark, which showed that the prevalence increased 
about  15­fold  from  1990  onwards,  yet  MMR  was 
introduced in Denmark in the 1970s, and thermasol was 
removed in the 1990s with no apparent impact. So I think 
it’s safe to say that vaccination is a red herring. Autism 
spectrum  disorders  are  now  recognized  to  be  a  fairly 
common condition, affecting almost 1% of children, and 
so there will be a substantial number of coincidences in 
which vaccination seems to trigger the condition.
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So  the  question  remains  why  there  has  been  such  a 
large increase since 1990. It is still unclear if there has 
been a real increase, because there are a number of other 
possible explanations that could account for much of the 
increase.  One  is  that  the  diagnostic  criteria  have 
broadened  enormously  since  1990.  Another  is  that 
parents, teachers, and doctors are much more aware of 
autism today than they were before, which is a big factor. 
Another  is  that,  in  the  1990s  in  America,  many  states 
provided special educational support for autistic children, 
so that parents were keen to have the diagnosis confirmed 
to  take  advantage  of  these  services,  which  no  doubt 
contributed to the increased prevalence, as well as to a 
decrease in the stigma associated with autism, which, in 
itself, would greatly increase the number of diagnoses.
To go back to genetics - How do you get from a 
rare mutation to the cause of the disorder in the 
common cases?
Now that you can sequence DNA increasingly cheaply 
and  quickly,  it  is  feasible  to  sequence  the  genomes  of 
large  numbers  of  autistic  individuals,  which  almost 
certainly will uncover increasing numbers of rare, big­
effect  mutations  that  contribute  to  the  disorder.  Once 
such a mutation is identified, one can try to produce the 
condition, or a part of it, in an experimental animal such 
as a mouse, where you can analyze the neurobiological 
basis of the problem. Once this has been done, which 
could take years, it will be necessary to go back to the 
humans with the same genetic problem to find out if the 
same cells, the same brain regions, the same synapses, 
and so on are involved.
One way to do this is to make induced pluripotent stem 
cells (iPSCs) ­ first from the mouse and then from autistic 
individuals with the same genetic problem. iPSCs closely 
resemble  ES  (embryonic  stem)  cells,  in  that  they  can 
proliferate  indefinitely  in  culture  and  be  induced  to 
differentiate  into  almost  any  type  of  cell  in  the  body, 
including  into  different  types  of  neurons.  Fortunately, 
developmental  neurobiologists  are  rapidly  figuring  out 
how to get many different types of neurons from such 
pluripotent stem cells. Once you have figured out how to 
get the appropriate types of neurons, you can let them 
form the synapses and circuits, either in a culture dish or 
after transplantation into a developing mouse brain, to 
show  that  you  can  reproduce  the  physiological  defects 
that you found in the mouse mutant. Then you would be 
ready to produce iPSCs from the autistic humans and use 
what you had learned studying the mouse iPSCs about 
how to produce the relevant types of neurons, synapses, 
and circuits that you think are affected, to see if you can 
reproduce the same type of physiological abnormalities. 
If you succeed, you can screen for drugs that can correct 
the problem and see if they can ameliorate the clinical 
problem.  All  of  this  will  be  difficult  and  very  time­
consuming, and it may not work, but, if it did, the payoff 
could be great, both in terms of new drugs and what it 
could potentially tell us about how the normal human 
brain works. I am optimistic, especially as many of the 
mouse  models  of  the  syndromic  forms  of  autism  have 
been  shown  to  be  at  least  partially  reversible  by 
treatments given to adult mice; this suggests that many of 
the  clinical  problems  may  result  from  reversible 
functional defects in the adult brain, rather than from 
irreversible anatomical defects that many believed to be 
the problem.
Where can I find out more?
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